LCM
CNTA

Lynx1 Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Lynx1 Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,400
Closed -$291K – 16
2024
Q4 		$291K Hold
17,400
– – 0.11% 16
2024
Q3 		$278K Hold
17,400
– – 0.1% 13
2024
Q2 		$157K Hold
17,400
– – 0.06% 15
2024
Q1 		$197K Buy
+17,400
New +$165K 0.05% 16

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lynx1 Capital Management's CNTA Position: Q1 2025 in Review

Lynx1 Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q1 2025, closing a stake of 17,400 shares — an estimated $291K sold.

Lynx1 Capital Management first reported a position in CNTA in Q1 2024 and held it in 4 quarters. The position peaked at $291K in Q4 2024. 129 funds tracked by Wall St. Rank hold CNTA as of Q1 2025.

  • Lynx1 Capital Management reported no remaining Centessa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Lynx1 Capital Management sold 17,400 Centessa Pharmaceuticals shares in Q1 2025, an estimated $291K.
  • Lynx1 Capital Management first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Lynx1 Capital Management's Centessa Pharmaceuticals position peaked at $291K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2025.

Based on Lynx1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.